Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood (2024) 144 (23): 2389–2401.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1

Blood (2022) 140 (Supplement 1): 4447–4449.

https://doi.org/10.1182/blood-2022-162555

Published: 2022

Journal Articles

A Phase 1/2 Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, PK and Efficacy of ZN-d5, a Novel BCL-2 Inhibitor, for Treatment of Subjects with Relapsed/Refractory AL Amyloidosis

Efstathios Kastritis, Jeffrey V. Matous, Emad Uddin Abro, P. Taylor Eves, Cheng Zheng, Tony Fiorino, Jesus Berdeja

Blood (2022) 140 (Supplement 1): 4438–4439.

https://doi.org/10.1182/blood-2022-158617

Published: 2022

Journal Articles

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Susan Bal, M. Hakan Kocoglu, Omar Nadeem, Myo Htut, Tara Gregory, Larry D. Anderson, Jr., Luciano J. Costa, Tonia J. Buchholz, Safiyyah Ziyad, Meng Li, Yanping Chen, Allison J. Kaeding, Michael R. Burgess, Kristen Hege, Jesus Berdeja

Blood (2022) 140 (Supplement 1): 883–885.

https://doi.org/10.1182/blood-2022-162395

Published: 2022

Journal Articles

Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

Emma Searle, Hang Quach, Sandy W. Wong, Luciano J. Costa, Cyrille Hulin, Wojciech Janowski, Jesus Berdeja, Sébastien Anguille, Jeffrey V. Matous, Cyrille Touzeau, Anne-Sophie Michallet, Marla Husnik, Deeksha Vishwamitra, Zhuolu Niu, Julie Larsen, Lingling Chen, Jenna D. Goldberg, Rakesh Popat, Andrew Spencer

Blood (2022) 140 (Supplement 1): 394–396.

https://doi.org/10.1182/blood-2022-159711

Published: 2022

Journal Articles

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

Saad Usmani, Krina Patel, Parameswaran Hari, Jesus Berdeja, Melissa Alsina, Ravi Vij, Noopur Raje, Xavier Leleu, Madhav Dhodapkar, Ran Reshef, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Revathi Ananthakrishnan, Chiara Greggio, Linda Favre-Kontula, Lars Sternas, Jesús San-Miguel

Blood (2022) 140 (Supplement 1): 875–877.

https://doi.org/10.1182/blood-2022-162469

Published: 2022

Journal Articles

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Blood (2022) 140 (Supplement 1): 384–387.

https://doi.org/10.1182/blood-2022-159707

Published: 2022

Journal Articles

KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation

Madhav Dhodapkar, Melissa Alsina, Jesus Berdeja, Krina Patel, Ravi Vij, Xavier Leleu, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Revathi Ananthakrishnan, Linda Favre-Kontula, Chiara Greggio, Lars Sternas, David Siegel

Blood (2022) 140 (Supplement 1): 7441–7443.

https://doi.org/10.1182/blood-2022-162615

Published: 2022

Journal Articles

Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival

Bruno Paiva, Irene Manrique, Julie A Rytlewski, Timothy B. Campbell, Christian Kazanecki, Nathan Martin, Shari M. Kaiser, Larry D. Anderson, Jr., Jesus Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, Philippe Moreau, Jesús San-Miguel, Nikhil C Munshi

Blood (2022) 140 (Supplement 1): 2104–2105.

https://doi.org/10.1182/blood-2022-166658

Published: 2022

Journal Articles

Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

Sosana Delimpasi, Meletios A. Dimopoulos, Jan Straub, Argiris Symeonidis, Roman Hájek, Cyrille Touzeau, Viralkumar K. Bhanderi, Jesus Berdeja, Petr Pavlíček, Jeffrey V. Matous, Pawel J. Robak, Kaveri Suryanarayan, Miguel Villareal, Dasha Cherepanov, Jaydeep K. Srimani, Huilan Yao, Richard Labotka, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 9995–9997.

https://doi.org/10.1182/blood-2022-163092

Published: 2022

Journal Articles

Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study

Noemi Puig, Vania T.M. Hungria, Ajai Chari, Faith E. Davies, Gordon Cook, Roman Hájek, Kathryn E. Morgan, Jim Omel, Evangelos Terpos, Michael A. Thompson, Saad Usmani, Jorge Vela-Ojeda, Katja Weisel, Mira Armour, Kaili Ren, Dasha Cherepanov, Dawn Marie Stull, Jesus Berdeja

Blood (2022) 140 (Supplement 1): 4269–4272.

https://doi.org/10.1182/blood-2022-163074

Published: 2022

Journal Articles

Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?

Blood (2021) 138 (Supplement 1): 2746.

https://doi.org/10.1182/blood-2021-152681

Published: 2021

Journal Articles

Multidisciplinary Provider Insights to Promote Adoption of Bispecific Antibodies to Treat Cancer in the Community

Limaya Atembina, Leigh Boehmer, Kelly Terrell, Rima Koka, Murali Janakiram, Axel Grothey, Amy L Morris, Srinivas Devarakonda, Barbara Rogers, Ronan Kelly, Jesus Berdeja, Firas El Chaer

Blood (2021) 138 (Supplement 1): 4033.

https://doi.org/10.1182/blood-2021-153794

Published: 2021

Journal Articles

A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma

Jesus Berdeja, Sikander Ailawadhi, Steven M. Horwitz, Jeffrey V. Matous, Neha Mehta-Shah, Thomas Martin, Eli Muchtar, Paul G. Richardson, Shambavi Richard, Manisha Bhutani, Andrew J. Yee, Michael R. Palmer, Cathleen Gorman, Oliver Schoenborn-Kellenberger, Sanela Bilic, Adam Crystal, Michelle Mahler, Sagar Lonial

Blood (2021) 138 (Supplement 1): 1675.

https://doi.org/10.1182/blood-2021-153575

Published: 2021

Journal Articles

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Blood (2020) 136 (22): 2513–2523.

https://doi.org/10.1182/blood.2020007522

Published: 2020

Includes: Supplemental data

Journal Articles

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

Ravi Vij, MBBS, MD, Carol Ann Huff, MD, William I. Bensinger, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Jesus Berdeja, MD, Nikoletta Lendvai, MD PhD, Daniel Lebovic, MD, Larry D. Anderson, MD PhD, Caitlin L. Costello, MD, Keith E. Stockerl-Goldstein, MD, Jacob P. Laubach, MD, Laurence Elias, MD, Fong Clow, ScD, Maria Fardis, PhD MBA, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Paul G. Richardson

Blood (2014) 124 (21): 31.

https://doi.org/10.1182/blood.V124.21.31.31

Published: 2014

Journal Articles

A Phase II Trial Evaluating the Safety of Rapid Infusion Ofatumumab (OFA) in Patients (pts) with Previously Treated Chronic Lymphocytic Leukemia (CLL)

William B. Donnellan, MD, Jesus Berdeja, MD, Dianna Shipley, MD, Edward Arrowsmith, MD MPH, David Wright, MD, Scott Lunin, MD, Richard H. Brown, MD, James Essell, MD, Ian Flinn

Blood (2014) 124 (21): 3336.

https://doi.org/10.1182/blood.V124.21.3336.3336

Published: 2014

Journal Articles

Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study

Jesus Berdeja, MD, Sundar Jagannath, MD, Jeffrey Zonder, MD, Ashraf Badros, MD, Jonathan L. Kaufman, MD, Robert Manges, MD, Mark Lynch, PhD, Eric Bleickardt, MD, Prashni Paliwal, PhD, Ravi Vij, MD

Blood (2014) 124 (21): 2119.

https://doi.org/10.1182/blood.V124.21.2119.2119

Published: 2014

Journal Articles

A Single-Arm, Open-Label, Multi-Center Phase I/II Study Of The Combination Of Panobinostat and Carfilzomib In Patients (pts) With Relapsed Or Relapse/Refractory Multiple Myeloma (MM)

Jesus Berdeja, MD, Michael Savona, MD, Joseph R Mace, MD, Lowell Hart, MD, James Essell, MD, Rami Owera, MD, Edward Arrowsmith, MD, MPH, Ian Flinn, MD, PhD

Blood (2013) 122 (21): 1937.

https://doi.org/10.1182/blood.V122.21.1937.1937

Published: 2013

Journal Articles

Array-Based Comparative Genomic Hybridization (aCGH) In Myelofibrosis Reveals Divergent Genetic Copy Number Alterations Among Patients With Post-Essential Thrombocythemia-Myelofibrosis/Post-Polycythemia Rubra Vera-Myelofibrosis (PET-MF and PPV-MF) and Patients With Idiopathic Myelofibrosis

Michael Savona, MD, Zeqiang Ma, PhD, Laura DeBusk, PhD, Pranil Chandra, DO, Shile Liang, PhD, R. Seth Cooper, MD, Eric Raefsky, MD, Victor Gian, MD, Richard Hockett, MD, Jesus Berdeja, MD, P. Alan Lennon, PhD

Blood (2013) 122 (21): 5266.

https://doi.org/10.1182/blood.V122.21.5266.5266

Published: 2013

NARROW

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1

A Phase 1/2 Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, PK and Efficacy of ZN-d5, a Novel BCL-2 Inhibitor, for Treatment of Subjects with Relapsed/Refractory AL Amyloidosis

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation

Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival

Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study

Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?

Multidisciplinary Provider Insights to Promote Adoption of Bispecific Antibodies to Treat Cancer in the Community

A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

A Phase II Trial Evaluating the Safety of Rapid Infusion Ofatumumab (OFA) in Patients (pts) with Previously Treated Chronic Lymphocytic Leukemia (CLL)

Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study

A Single-Arm, Open-Label, Multi-Center Phase I/II Study Of The Combination Of Panobinostat and Carfilzomib In Patients (pts) With Relapsed Or Relapse/Refractory Multiple Myeloma (MM)

Array-Based Comparative Genomic Hybridization (aCGH) In Myelofibrosis Reveals Divergent Genetic Copy Number Alterations Among Patients With Post-Essential Thrombocythemia-Myelofibrosis/Post-Polycythemia Rubra Vera-Myelofibrosis (PET-MF and PPV-MF) and Patients With Idiopathic Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only